DEARhealth: Chronic Disease Management Platform

VENICE, California., May 27th, 2020: DEARhealth Inc., a health tech company focused on AI-powered disease management, announced today the global launch of its DEARhealth platform in the Epic App Orchard online marketplace. Organizations using Epic, including health systems, hospitals, and clinics, can now access DEARhealth directly through the marketplace instead of traditional external integration, saving significant time, costs, and staff resources.

SWORD Health Extends to $17M

New York, February 27th, 2020: SWORD Health (SWORD), a tech-enabled provider of musculoskeletal care, today announced the addition of $9 million to their Series A investment, bringing their total Series A investment to $17 million.

Prothesenfüße aus dem 3D-Drucker

Munich, January 20th, 2020 – Prosthetic feet from the 3D printer are no longer an utopia, but reality. The combination of designing a foot in the computer and fast production through 3D printing creates a completely new ability to act, as Mercuris GmbH proves.

OncoDNA Closes Investment Round

Gosselies, Belgium – February 14th, 2020 – OncoDNA ("OncoDNA or "the Company"), the healthcare technology company making precision medicine a reality, today announced that it has completed a €19 million ($20 million) Series B equity financing.

Mecuris GmbH: New CEO at the helm

Munich, Germany / February 10th, 2020. – Successful Munich-based medical technology company Mecuris will be led by a new CEO, Peter Fröhlingsdorf (50), a renowned industry expert. Since the beginning of January this year, Fröhlingsdorf has been managing the business of the up-and-coming medtech scale-up. The main goal for this financial year is to lead the company from the start-up into the growth phase. The CEO's expertise and numerous years of industry know-how will be decisive in this process.

New Growth Funding Mecuris GmbH

Munich, Germany, January 13th, 2020 – German med-tech company Mecuris GmbH has successfully concluded a new funding round amounting to 3.6 million euros. In addition to the seed investors Bayern Kapital and High-Tech Gründerfonds (HTGF), the international investment company Mulcan, life science venture capital investor Vesalius Biocapital, and Sana Kliniken AG, one of the top five hospital chains in Germany, are once again also on board.

3D-Druck in der Medizintechnik

München, 13.12.2019 – Die Bundesregierung sieht großes Potenzial im Einsatz von 3D-Druck in der Medizintechnik – insbesondere für patientenindividuelle Sonderanfertigungen von Prothesen oder Orthesen. Das geht aus der Antwort auf die kleine Anfrage der FDP-Bundestagsfraktion „Prothesen aus dem 3D-Drucker für Menschen mit Behinderungen" hervor.

Forendo Pharma Deal with Novartis

Turku, Finland, December 11th 2019: Forendo Pharma, a clinical stage drug development company focusing on novel treatments in women's health, today announces signing of a License and Collaboration Agreement with Novartis. The joint research collaboration is aimed at the identification of novel drugs for the treatment of chronic liver diseases. Novartis receives a worldwide exclusive license to drug candidates generated under the collaboration.

Tonic App raises 3.5 million euros

August 27th 2019: Tonic App, the startup that developed the favourite mobile application of more than 12,000 medical doctors, has raised 3.5 million euros in a round co-led by Vesalius Biocapital Partners (Luxembourg) and Armilar Venture Partners (Portugal), joining Portugal Ventures and TheVentureCity.

Mecuris GmbH: Best MedTech Startup

Mecuris GmbH, a commercial-stage Munich-based medical technology startup focusing on the digitalization of prosthetics and orthotics, has been listed as one of the Best European MedTech Startups by Valuer. Vesalius Biocapital supports the innovative Mecuris approach since January 2019.